Department of Health and Human Services

OFFICE OF INSPECTOR GENERAL

MEDICARE PAYMENTS FOR NEWLY AVAILABLE GENERIC DRUGS

Daniel R. Levinson
Inspector General

January 2011
OEI-03-09-00510
EXECUTIVE SUMMARY

OBJECTIVES

1. To estimate the financial impact of the two-quarter reimbursement lag on Medicare payments for Part B-covered drugs with newly available generic versions.

2. To estimate when high-expenditure brand-only Part B-covered drugs will likely have first-generic versions reach the market.

BACKGROUND

Although Medicare Part D covers most prescription drugs, Part B continues to cover a limited number of outpatient prescription drugs. Payment for most Part B-covered drugs is equal to 106 percent of the average sales price (ASP) for all versions of a drug. Manufacturers are required to submit ASP data to the Centers for Medicare & Medicaid Services (CMS) within 30 days after the close of each quarter, and the data are used to calculate the payment amount for the following quarter. As a result, there is a two-quarter lag between when sales occur and when the payment amount reflects those sales. This reimbursement lag is especially problematic when newly available generic drugs enter the market, as their ASPs are often substantially lower than their brand counterparts, but payment amounts remain at the higher brand level for two quarters or more.

A previous Office of Inspector General (OIG) report highlighted the vulnerabilities of the two-quarter lag by estimating the amount that Medicare would have saved if reimbursement had been based on actual market sales prices for one high-expenditure Part B-covered drug. OIG recommended that CMS explore options to ensure that payment amounts reflect actual market prices in a more timely manner. CMS concurred with our recommendation; however, as of May 2010, CMS has yet to make any changes to its reimbursement process.

For this study, we examined the Medicare payment amounts for 16 Part B-covered drugs that we identified as having first-generic versions reach the market in 2007, 2008, or the first two quarters of 2009. For each of the drugs, we determined how much Part B spending would have decreased had there been no two-quarter lag during the initial period of generic availability (i.e., the first three quarters in which generics were available). We then totaled these figures to determine the net financial impact of the two-quarter lag on Part B and its beneficiaries. To provide context for the future impact of the
EXECUTIVE SUMMARY

two-quarter lag, we also requested from the Food and Drug Administration (FDA) the estimated date of generic approval for the top dollar-volume brand drugs covered under Part B.

FINDINGS

Medicare could have saved an estimated $111 million had payment amounts immediately reflected generic sales prices for 16 drugs. The financial impact of the two-quarter reimbursement lag in the period of initial generic availability for 16 newly available generic drugs totaled approximately $111 million. These potential savings accounted for 25 percent of total expenditures for these drugs during the same period. It is not just the program itself, but also Medicare beneficiaries who feel the financial effect of the reimbursement lag (because of cost sharing).

Furthermore, it may take years for Medicare to realize the full savings of generic versions. The average payment amounts for the drugs under review continued to decline beyond the period of initial generic availability, ending with an average payment amount 2 years after the introduction of generics that was nearly 60 percent less than that of the original brand-only payment amount. Additionally, brand drugs were initially 3 times more expensive than their generic versions, on average.

According to FDA, numerous high-expenditure drugs could have first-generic versions approved in the next several years. According to FDA, 26 of the 48 top dollar-volume brand drugs covered under Part B either already have or could have generic versions approved for the first time in the next several years. These 26 drugs had combined Part B expenditures of over $2.8 billion in 2009. The remaining 22 drugs are biologics, which comprise nearly half of all current high-dollar brand-only Part B drugs, and (because of recent legislation) may have generic versions approved in the future. Part B spending on the top 22 biologics totaled over $5.3 billion in 2009.

Significant obstacles remain in proactively identifying newly available generic drugs. Although FDA publishes the date of approval for first generics, this date is often not an accurate indicator of the entry of generic versions into the market because issues such as patent litigation and marketing agreements may affect the date of generic availability. Our analysis identified a number of drugs with FDA-estimated dates of generic approval that did not coincide with the generic market entry dates, including two drugs FDA identified as
having first-generic versions but appear to have never reached the market. For another group of drugs, generic manufacturers failed to report ASPs in a timely manner, increasing the difficulty in setting payment amounts that accurately reflect sales of newly available generic drugs.

**RECOMMENDATION**

This is the second OIG report to identify systemic vulnerabilities in Part B as a result of the two-quarter lag in payments for newly available generic drugs. We found that Medicare payment amounts were significantly higher than market prices for an extended period for the newly available generic drugs under review. In other words, generic versions of these drugs were being administered or dispensed to beneficiaries, but Medicare was still paying brand prices. Although other government and privately sponsored prescription drug programs are designed to take advantage of lower-priced generic drugs, our findings demonstrate that the Part B reimbursement system fails to capture these potential savings for at least two quarters.

With more than half of the top dollar-volume brand drugs covered under Part B potentially gaining approval in generic form over the next 4 years, and the creation under the Patient Protection and Affordable Care Act of a new approval pathway for generic biologics, this vulnerability will likely continue to grow if CMS does not make changes to its Part B payment system. We therefore recommend that:

**CMS work with Congress to require manufacturers of first generics to submit monthly ASP data during the period of initial generic availability.** By requiring manufacturers of first generics to report ASPs on a monthly basis when the generics first become available, CMS could substantially reduce the two-quarter lag and make Medicare payment amounts more reflective of actual market prices. If CMS finds this to be an effective means for alleviating the financial impact of the two-quarter lag, the agency may wish to consider requiring monthly ASP submissions for all Part B-covered drugs.

**AGENCY COMMENTS AND OFFICE OF INSPECTOR GENERAL RESPONSE**

CMS did not concur with our recommendation, citing potential problems with manufacturer price submissions and increased administrative burdens under a proposed monthly ASP reporting requirement. CMS
also stated that it believes the two-quarter lag protects Medicare and its beneficiaries from unchecked price increases and is an incentive for faster generic utilization.

Because of the two-quarter lag, Part B and its beneficiaries are denied significant potential savings when generic versions first become available. Therefore, we believe that the savings from a reduced reimbursement lag may outweigh any difficulties with implementing a monthly ASP reporting system. Furthermore, we note that the ASP-based reimbursement system (in which all versions of a drug assigned to one payment code are paid at the same amount) is a natural incentive for manufacturers to limit rapid price increases, as well as for providers to utilize generic versions.
# Table of Contents

**Executive Summary** ................................................................. i

**Introduction** ................................................................. 1

**Findings** ................................................................. 13

Medicare could have saved an estimated $111 million had payment amounts immediately reflected generic sales prices for 16 drugs. ................................................................. 13

According to FDA, numerous high-expenditure drugs could have first-generic versions approved in the next several years ...... 15

Significant obstacles remain in proactively identifying newly available generic drugs ................................................................. 16

**Recommendation** ................................................................. 19

Agency Comments and Office of Inspector General Response ... 20

**Appendices** ................................................................. 23

A: Detailed Methodology for Identifying First-Generic Drugs and Their Dates of Market Entry ................................................................. 23

B: First-Generic Drugs Included in Our Analysis ................................................................. 25

C: Medicare Payment Amounts for 16 Newly Available Generic Drugs ................................................................. 26

D: Estimated Generic Approval Timeline for the Top 26 Dollar-Volume Brand-Only Part B Drugs (Biologics Excluded), According to FDA ................................................................. 28

E: Top 22 Dollar-Volume Biologics Under Part B ................................................................. 29

F: Comparison of FDA’s ANDA Approval Dates and Actual Generic Entry Dates ................................................................. 30

G: Agency Comments ................................................................. 31

**Acknowledgments** ................................................................. 36
INTRODUCTION

OBJECTIVES

1. To estimate the financial impact of the two-quarter reimbursement lag on Medicare payments for Part B-covered drugs with newly available generic versions.

2. To estimate when high-expenditure brand-only Part B-covered drugs will likely have first-generic versions reach the market.

BACKGROUND

In 2009, Medicare spent approximately $11 billion on Part B-covered drugs.\(^1\) Medicare pays for most prescription drugs covered under Part B based on manufacturer-reported average sales prices (ASP). Because payment amounts are determined using ASP data from two quarters earlier, it may take 6 months or more for Medicare reimbursement to reflect any price changes in the marketplace.

A previous Office of Inspector General (OIG) report\(^2\) found that this two-quarter reimbursement lag had negative financial consequences for the Medicare program and its beneficiaries (through higher coinsurance) when lower-priced generic versions of the cancer drug irinotecan first reached the market. In its comments to that report, the Centers for Medicare & Medicaid Services (CMS) concurred with our recommendation that the agency explore options that would allow payment amounts to more accurately reflect new generic prices. CMS stated that it is interested in any suggestions OIG may have to improve the methods used to collect and array data under the ASP system.\(^3\) However, CMS has yet to make any changes that would allow Medicare to take advantage of the lower prices of newly available generic drugs in a more timely manner. To that end, this study expands on previous work by examining the impact of the two-quarter lag on a broader scale.

Payment for Medicare Part B-Covered Drugs

Although Medicare Part D covers most outpatient prescription drugs, CMS continues to cover a limited number of outpatient prescription drugs and biologicals (hereinafter referred to as drugs) under its Part B benefit. Part B-covered drugs generally fall into the following categories:

---


\(^2\) OIG, Medicare Payment for Irinotecan, OEI-03-08-00310, August 2008.

\(^3\) Ibid.
categories: drugs furnished incident to a physician’s service (e.g., injectable drugs used in connection with the treatment of cancer), drugs explicitly covered by statute (e.g., some vaccines and oral anticancer drugs), and drugs used in conjunction with durable medical equipment (e.g., inhalation drugs).4

To obtain Medicare payment for Part B-covered drugs, physicians and suppliers submit claims, using the Healthcare Common Procedure Coding System (HCPCS) codes, to claims-processing contractors. The HCPCS codes provide a standardized system for describing specific items and services provided in the delivery of health care. In the case of prescription drugs, each HCPCS code defines the drug ingredient name and billing unit size but does not specify the manufacturer or package size. As a result, HCPCS codes for single-source drugs (i.e., drugs with no available generic versions) typically include products from only one manufacturer, and HCPCS codes for multiple-source drugs (i.e., drugs with generic versions) include products from multiple manufacturers.

CMS pays for most Part B-covered drugs based on their ASPs.5 The ASP is defined as a manufacturer’s sales of a drug to all purchasers in the United States in a calendar quarter divided by the total number of units of the drug sold by the manufacturer in that same quarter.6 The ASP is net of any price concessions, such as volume discounts, prompt-pay discounts, cash discounts, free goods contingent on purchase requirements, chargebacks, and rebates other than those obtained through the Medicaid drug rebate program.7 Sales that are nominal in amount are exempted from the ASP calculation, as are sales excluded from the determination of “best price” in the Medicaid drug rebate program.8, 9

Medicare payment amounts for most Part B-covered prescription drugs are equal to 106 percent of the volume-weighted ASPs for the HCPCS

---

5 Several Part B drugs, including certain vaccines and blood products, are not paid under the ASP methodology.
6 Section 1847A(c) of the Social Security Act (the Act), as added by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), P.L. 108-173.
7 Section 1847A(c)(3) of the Act.
8 Pursuant to section 1927(c)(1)(C)(i) of the Act, “best price” is the lowest price available from the manufacturer during the rebate period to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity within the United States, with certain exceptions.
9 Section 1847A(c)(2) of the Act.
codes. Medicare beneficiaries are responsible for 20 percent of this amount in the form of coinsurance.

**Manufacturer Reporting Requirements**

*ASP data.* Manufacturers with Medicaid drug rebate agreements in effect must, among other things, provide CMS with pricing information, including the ASP for each of their Part B-covered drugs and the average manufacturer price (AMP) for each of their Medicaid-covered drugs.\(^\text{10, 11}\) Manufacturers report ASPs for Part B-covered drugs by national drug codes (NDC), which are 11-digit numeric codes divided into three segments identifying (1) the firm that manufactures, distributes, or repackages\(^\text{12}\) the drug product (i.e., the labeler code); (2) the specific strength, dosage form, and formulation of the product; and (3) the product’s package size. Manufacturers are required to provide CMS with the ASP and volume of sales for each NDC within 30 days of the end of each quarter.\(^\text{13}\) Because Medicare payment for Part B-covered drugs is based on HCPCS codes rather than NDCs and more than one NDC may meet the definition of a particular HCPCS code, CMS has developed a file that “crosswalks” manufacturers’ NDCs to HCPCS codes.

Manufacturers may face civil money penalties or suspension of their rebate agreements if they knowingly provide false information about their ASPs, fail to report ASP data in the required timeframe, or make misrepresentations in reporting ASPs.\(^\text{14}\) The penalties associated with late submissions may be increased by up to $10,000 for each day ASP data are not provided.\(^\text{15}\)

**The Two-Quarter Lag in Reimbursement for Part B-Covered Drugs**

CMS’s ASP payment methodology has an inherent lag between the time when sales occur and when the sales become the basis for payment amounts. Manufacturers must provide CMS with the required ASP

---

\(^\text{10}\) For Federal payment to be available for covered outpatient drugs provided under Medicaid, sections 1927(a)(1) and (b)(1) of the Act mandate that drug manufacturers enter into rebate agreements with the Secretary of Health & Human Services and pay quarterly rebates to State Medicaid agencies.

\(^\text{11}\) Medicaid rebates are based on AMPs. ASPs are not used in the calculation of Medicaid rebates.

\(^\text{12}\) A repackager purchases drugs from manufacturers and typically repackages them into smaller quantities.

\(^\text{13}\) Section 1927(b)(3) of the Act and 42 CFR § 141.480(a)(5).

\(^\text{14}\) Sections 1927(b)(5)(C)(i) and (ii) of the Act and § 1847A(d)(4) of the Act.

\(^\text{15}\) Section 1927(b)(3)(C)(i) of the Act.
data for each NDC within 30 days after the close of each quarter. CMS then calculates a volume-weighted ASP for each HCPCS code. This ASP becomes the basis for the payment amount for the following quarter. For example, third-quarter 2009 ASP data from manufacturers were due to CMS 30 days after the end of the third quarter (i.e., October 30, 2009), which CMS used as the basis for first-quarter 2010 Medicare payment amounts. See Table 1 for a description of the reimbursement timeline.

Table 1: ASP-Based Reimbursement Timeline

<table>
<thead>
<tr>
<th>Manufacturer Sales Period</th>
<th>ASP Data Due to CMS</th>
<th>Quarter in Which ASP-Based Payment Amount Applied</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-Quarter 2009</td>
<td>Apr. 30, 2009</td>
<td>Third-Quarter 2009</td>
</tr>
<tr>
<td>Second-Quarter 2009</td>
<td>July 30, 2009</td>
<td>Fourth-Quarter 2009</td>
</tr>
<tr>
<td>Third-Quarter 2009</td>
<td>Oct. 30, 2009</td>
<td>First-Quarter 2010</td>
</tr>
</tbody>
</table>


The two-quarter lag causes Medicare and its beneficiaries to miss out on immediate savings anytime a drug’s ASP declines, as the payment amount to providers (e.g., physicians and pharmacies) remains at the previous (higher) level for two quarters or more—even though these providers are acquiring the drug at the recently reduced price. This is especially relevant when generic versions of a drug first become available. Typically, when the first-generic\(^\text{16}\) version of a drug enters the market, its sales prices are substantially lower than those of the drug’s brand equivalent. Additionally, generic versions often quickly account for the majority of utilization for that drug, overtaking the more expensive brand form. However, because of the two-quarter lag in the ASP calculation, the lower prices and increased utilization of generic versions are not immediately factored into calculations of the Medicare payment amount for the corresponding HCPCS code. Therefore, provider acquisition costs for these drugs will most likely decrease substantially in the first quarter of generic availability, although Medicare payment amounts will take at least two quarters to reflect the change.

\(^\text{16}\) Hereinafter, the term “first generic” will refer to the initial generic version(s) of a drug approved under an Abbreviated New Drug Application (ANDA) as listed by the Food and Drug Administration (FDA) on the First-Time Generic Drug Approvals list. FDA, ANDA (Generic) Drug Approvals. Accessed at http://www.fda.gov on April 27, 2010.
FDA’s Generic Approval Process
Brand drugs are given patent protection by the U.S. Patent and Trademark Office for a certain period (generally 20 years from the date of filing). Upon approval by FDA, manufacturers are also granted market exclusivity for the drug, which may or may not run concurrently with the patent protection. With certain exceptions, generic drugs cannot be marketed before the brand drug’s patent and market exclusivity expire. Before marketing a generic version of a brand drug, a pharmaceutical company must obtain FDA approval by submitting an ANDA. Generally, a generic drug must be the same as a brand drug with respect to conditions of use (with certain exceptions), active ingredient(s), route of administration, dosage form, strength, and labeling. In addition, with certain exceptions, the generic drug must be bioequivalent to (i.e., perform in the same manner as) the brand drug.

Each month, FDA publishes a list of new first-time generic drug approvals (note: the approval of a drug does not mean that it reaches the market). Furthermore, the FDA Approved Drug Products directory ("Drugs@FDA") provides each drug’s approval history, including whether it was approved under an ANDA, thereby indicating a generic drug. Drugs@FDA is searchable by application number, proprietary drug name, and active ingredient.

Previous OIG Work
A 2008 OIG report identified vulnerabilities in the Part B payment system when the first-generic versions of a prescription drug enter the market. In that report, we estimated that providers paid $51.59 per 20 milligrams of irinotecan (a cancer drug that was available in generic

---

19 Ibid.
21 21 CFR § 314.105(d).
25 OIG, Medicare Payment for Irinotecan, OEI-03-08-00310, August 2008.
form beginning in February 2008) in the first quarter of 2008. The Medicare payment amount in the same quarter was more than double that amount ($126.31). We found that Medicare expenditures could have been reduced by an estimated $26 million had Medicare reimbursement immediately reflected actual market prices between March and June 2008 (the period in which payment amounts were still fully based on the brand prices).

We recommended that CMS explore options (including a possible legislative change) that would allow payment amounts to more accurately reflect new generic prices. CMS concurred with our recommendation and expressed its commitment to ensuring accurate payments for drug products under the ASP methodology, including working with OIG to improve the methods CMS uses to collect data. However, as of May 2010, CMS has not taken any actions to address potential overreimbursement for first generics.

**METHODOLOGY**

**Data Sources**
The following data sources were used in our analysis to identify newly available generic drugs, calculate the financial impact of the two-quarter lag, and estimate when high-expenditure brand-only Part B-covered drugs will likely have first-generic versions reach the market.

**FDA’s monthly list of first-generic drug approvals.** Each month, FDA publishes on its Web site a list of first-time generic drug approvals. This list contains the drug name, form, strength, and manufacturer of each first-generic drug approved in that month. It does not list the NDCs or HCPCS codes for the newly approved drugs.

**FDA’s Approved Drug Products directory (“Drugs@FDA”).** This FDA directory contains the approval history of all drugs, including approved labels and whether a drug was approved under a New Drug Application or ANDA. It does not list any of this information by NDC or HCPCS code.

---


**FDA staff.** We requested information from staff at FDA relating to the generic approval status of certain high-expenditure brand-only drugs covered under Part B.

**CMS’s quarterly crosswalk file.** Each quarter, CMS publishes a file that lists all NDCs that correspond to each HCPCS code for drugs paid under Part B.\(^{28}\)

**CMS’s quarterly Part B payment-limit file.** Each quarter, CMS posts a file containing the payment amount by HCPCS code for drugs paid under Part B.\(^{29}\)

**CMS’s quarterly ASP background file.** CMS provides OIG with the ASP background file each quarter. This file contains ASP data (including the ASP itself and the number of units sold in the quarter) for all NDCs (grouped by their corresponding HCPCS codes) that were reported in that quarter. The data in this file are used to calculate the payment amount for each HCPCS code as listed in the quarterly Part B payment-limit file.

**CMS’s monthly AMP file.** CMS provides OIG with a file containing manufacturer-reported AMP data each month. AMP data\(^{30}\) are used in the determination of rebates under the Medicaid drug rebate program and are reported by the NDC.

**CMS’s labeler file.** CMS publishes a file that lists each manufacturer with a Medicaid drug rebate agreement, the agreement’s effective date, and the manufacturer’s labeler code (i.e., the first five digits of the NDC).\(^{31}\)

**CMS’s Part B quarterly utilization data.** Quarterly Part B utilization data for prescription drugs are available through CMS’s Part B Extract and Summary System (BESS) and PBAR system. These data provide the

---


\(^{30}\) Section 6001(b)(1)(A) of the Deficit Reduction Act of 2005 requires manufacturers, beginning January 1, 2007, to report AMPs to CMS on both a monthly and a quarterly basis, with monthly submissions due 30 days after the close of each period. As generally defined in section 1927(k)(1) of the Act, as amended by section 2503(a)(2) of the Patient Protection and Affordable Care Act (ACA), P.L. 111-148, the AMP is the average price paid to manufacturers for drugs in the United States by wholesalers for drugs distributed to retail community pharmacies and by retail community pharmacies that purchase drugs directly from manufacturers.

total units and total amount reimbursed for each HCPCS code during a given quarter or year.

**Micromedex’s quarterly Red Book file.** The Red Book file is an industry-produced compendium containing drug product information and pricing data at the NDC level. OIG receives updated Red Book data each quarter.

**Manufacturer online press releases.** Through manufacturer Web sites and online trade publications, manufacturers periodically announce the launch of recently approved generic drugs.

**Identification of Newly Available Generic Drugs**

We consulted FDA’s monthly list of first-generic drug approvals to identify all drugs that had first-generic versions potentially become available in 2007, 2008, or the first two quarters of 2009. We compared this list of drugs to CMS’s Part B crosswalk files to determine which of these first-generic drugs were covered under Part B and reimbursed based on the ASP payment methodology.

Because issues such as patent infringement litigation prevent some FDA-approved first generics from becoming available or available immediately after approval, we performed the following additional checks to determine whether Part B drugs on FDA’s list actually reached the market in 2007, 2008, or the first two quarters of 2009:

1. We first used CMS’s quarterly ASP background files to determine the number of manufacturers that reported sales of potential first-generic drugs covered under Part B and the drugs’ corresponding NDCs. Because manufacturers are required to submit quarterly ASP data to CMS, the background files enabled us to identify the number of manufacturers that sold each drug in each quarter, thereby confirming whether FDA’s first-generic approval date coincided with the market entry of new manufacturers for each drug. However, because previous OIG work found that manufacturers do not always report ASPs in a timely manner,

---

32 Because there is often a gap between the time when a drug receives FDA approval and when it becomes available on the marketplace, we also included drugs from FDA’s list of generic drugs approved in November and December 2006 if data sources indicated they did not become available until 2007.

33 OIG, *Average Sales Prices: Manufacturer Reporting and CMS Oversight*, OEI-03-08-00480, February 2010.
also took additional steps to identify whether and when a product reached the market.

2. We performed similar checks using CMS’s monthly AMP files and Micromedex’s Red Book file to further confirm the date of the first reported sales of each generic drug. By matching the NDCs reported by each generic manufacturer in the ASP background files to the NDCs listed in the AMP files, we were able to determine the first month that generic sales were reported to CMS. The same NDCs were also used to determine the first quarter that generic manufacturers reported product information to Red Book, which served as an additional confirmation of the date of generic market entry.

3. As a final check, we reviewed generic manufacturer online press releases announcing the availability of generic drugs to confirm the date of market entrance.

This process produced a final list of 16 Part B drugs that had first-generic versions appear on the market in 2007, 2008, or the first two quarters of 2009.34, 35

For some drugs, not all of these data sources mentioned above provided the same date of generic entry. With most discrepancies, we chose the consensus date among most of these data sources. When there was no clear consensus (3 of the 16 drugs), we deferred to the first full month of generic sales listed among all data sources.

In some instances, these date discrepancies indicated a failure of manufacturers to report ASPs, as required. For example, comparing NDCs in the quarterly ASP background files to those listed in the

---

34 Our analysis initially identified 18 first-generic drugs. Two drugs (levalbuterol inhalation solution unit dose and levalbuterol inhalation solution concentrate) reached the market, but coding and payment issues created difficulties with any analysis. In general, for much of the review period, Medicare payment amounts for levalbuterol were not based solely on its own ASPs, but also on the ASPs for a different drug (albuterol) as well. The removal of these 2 drugs brought the final number of first generics under review to 16. See the OIG report entitled Beneficiary Utilization of Albuterol and Levalbuterol Under Medicare Part B, OEI-03-07-00440, August 2009, for a full description of the numerous coding and payment changes for levalbuterol since 2003.

35 We use the term “drug” here to describe a unique HCPCS code: the final list included 16 unique HCPCS codes, representing 14 drug ingredients (granisetron hydrochloride had separate HCPCS codes for injection and tablet forms, and dronabinol oral had separate HCPCS codes for 2.5 mg and 5 mg), but because each HCPCS code has its own Part B payment amount, we considered the total list of first generics to include 16 drugs.
monthly AMP files enabled us to determine whether generic manufacturers were late to report ASPs. In such cases, we used the CMS labeler files to determine whether those manufacturers had a Medicaid drug rebate agreement (and thus were required to submit ASPs). See Appendix A for a detailed description of our methodology for identifying first generics.

Financial Impact of the Two-Quarter Lag During Initial Generic Availability
To determine the financial impact of the reimbursement lag for the 16 newly available generic drugs, we first calculated the effect the lag had on payment amounts in each quarter. We did this by comparing the Part B payment amount from CMS’s payment-limit file in the quarter under review to the payment amount from two quarters later. Because the payment amount from two quarters later was based on sales that occurred during the quarter under review, it served as an estimate of what the payment amount would have been had there been no lag. To determine the amount spending would have decreased had this payment amount been in effect, we (1) calculated the percentage difference between the payment amount during the quarter under review and the payment amount from two quarters later and (2) multiplied the percentage difference by the total amount reimbursed in that quarter.

We performed this analysis during the initial generic availability period of each drug: i.e., the quarter in which generics were first available in the market, as well as the subsequent two quarters—yielding three quarters of analysis for each drug. Although payment amounts are always based on ASPs from two quarters previous, the initial effects of the lag often extend into the third quarter of generic availability. For example, if a first generic did not become available until the middle of a quarter (e.g., February 15, 2008), the volume-weighted ASP for that quarter (first-quarter 2008) will not reflect a full period of sales of generic versions—and consequently, the drug’s Medicare payment amount in third-quarter 2008 will only reflect partial generic sales. As a result, the effects of the reimbursement lag will still be felt in the third quarter of 2008 (i.e., the third quarter of generic availability).

---

36 We obtained utilization data from BESS and PBAR for each quarter and drug under review.

37 For the purpose of this analysis, a two-quarter reimbursement lag is assumed for all newly available generic drugs.
including the third quarter of generic availability in our financial impact analysis, we were able to account for these extended effects.

In instances in which a first generic was approved after the first month of a quarter (and therefore was available for only a portion of the quarter), we used proportional utilization data to reflect the amount of time the generics were available in that quarter.\(^{38}\)

Once we estimated the financial impact for each drug, we totaled these figures to determine the net financial impact of the two-quarter reimbursement lag on Part B and its beneficiaries for the 16 drugs over their initial periods of generic availability. We compared the total potential savings to the total amount reimbursed for all drugs over the same period and determined the proportion of potentially excessive expenditures resulting from the two-quarter lag.

**Comparison of generic and brand ASPs.** The volume-weighted ASP for a HCPCS code is calculated using the individual ASPs for all corresponding NDCs. Within each HCPCS code, the ASPs for the brand and any generic NDCs often vary considerably (even though the Medicare payment amount is the same for all NDCs under a HCPCS code). To highlight the difference between generic-only and brand-only ASPs when a generic version first becomes available, we used CMS’s background files to separately calculate the volume-weighted ASP of generic and brand versions of each drug in the first quarter in which the generics were available.\(^{39}\)

**Analysis of payment levels beyond the period of initial generic availability.** Even after generics become fully accounted for in the Medicare payment amount (i.e., after the period of initial generic availability), the two-quarter lag may still have a negative effect if market prices continue to fall. Therefore, in addition to quantifying the financial impact of the two-quarter lag during the period of initial generic availability, we also tracked Medicare payment amounts for the 16 drugs for up to 2 years\(^ {40}\) after their first-generic versions became available. To do so, we compared the Medicare payment amounts during the quarter before generics became available to the payment...

---

\(^{38}\) CMS’s AMP files allowed us to determine the first month of generic availability.

\(^{39}\) Data were unavailable for two drugs.

\(^{40}\) Because three drugs did not reach the market until first- or second-quarter 2009, payment amounts for these drugs were not available for the full 2 years.
amounts 2 years later. By comparing the Medicare payment amounts before and after generic sales were reflected in the volume-weighted ASPs, we were able to illustrate the long-term effect of generics on Medicare payment amounts as well as how the two-quarter lag may continue to affect payment after the period of initial generic availability.

Identification of Future First-Generic Drugs
We provided FDA with a list of the top 48 brand-only drugs (by Medicare expenditure) covered under Part B and requested an estimate of when each drug was likely to have first-generic versions receive approval. To compile the list, we researched the top dollar-volume drugs covered under Part B in 2008 to determine which drugs were available only in brand form. FDA provided the estimated date of generic approval for each brand drug based on when an ANDA could first be approved.

Limitations
Our analysis was based on data provided by FDA and CMS, and we did not verify the data’s accuracy or completeness. Additionally, FDA’s generic approval timeline for brand drugs was based only on the estimated date of possible ANDA approval and did not take into account other factors (e.g., patent litigation) that may affect the date of actual market entry.

Standards
This study was conducted in accordance with the Quality Standards for Inspections approved by the Council of the Inspectors General on Integrity and Efficiency.

---

41 The 2 years varied for each drug, but our analysis did not extend beyond second-quarter 2010.
42 Originally, we provided FDA with a list of 50 brand-only drugs. We removed two drugs from this list after we determined that first-generic versions had been approved by FDA. In the case of mycophenolate mofetil, our data sources contained no evidence at the time we originally contacted FDA that generics had reached the market (although they subsequently did during the period covered by our review). In the case of budesonide, first-generic versions had been approved and had briefly reached the market; however, as the result of patent litigation, no generic versions remained on the market during the period covered by our analysis. This brought the final list to 48 brand-only drugs.
43 We used CMS’s background files, manufacturer Web sites, and FDA’s list of generic drug approvals to determine whether a drug was brand-only or available in generic form.
Medicare could have saved an estimated $111 million had payment amounts immediately reflected generic sales prices for 16 drugs. Had there been no two-quarter reimbursement lag during the period of initial generic availability for 16 drugs, we estimate that Medicare and its beneficiaries could have saved $111 million. The potential savings accounted for 25 percent of Part B expenditures for these drugs in their period of initial generic availability. Three drugs each had an estimated $20 million or more in total potential savings over the course of the three quarters under review. See Appendix B for a list of each drug’s potential savings.

Because of cost-sharing obligations, Medicare beneficiaries also experience the financial effect of the reimbursement lag. For example, when the oral version of the antiemetic drug granisetron first became available in generic form in first-quarter 2008, providers who purchased the generic version paid, on average, $12.89 per milligram (mg). The Medicare payment amount that quarter ($50.22 per mg), however, was based only on brand versions. As a result, the 20-percent beneficiary coinsurance at this time ($10.04 per mg) was only slightly less than the entire acquisition cost of the generic drug.

Because of the reimbursement lag, it may take years for Medicare to realize the full savings of generic versions. The negative effects of the reimbursement lag are not necessarily limited to the first three quarters of generic availability. Medicare payment amounts will exceed actual market prices anytime ASPs decline. Therefore, when ASPs for a drug with new generic versions decline.

Notes:

44 The period of initial generic availability is defined as the first three quarters generic versions were available.
45 Savings estimates for each drug were based on three quarters of analysis (i.e., the period of initial generic availability), but because the 16 drugs became available in generic form at different times, the three quarters under review varied from drug to drug.
46 Because generic manufacturers for two of the drugs in our analysis did not report any ASPs, we could not calculate the financial impact of new generic versions of these two drugs.
47 These drugs were mycophenolate mofetil oral, albuterol sulfate/ipratropium bromide inhalation solution, and irinotecan injection. Irinotecan may be atypical in that numerous generic manufacturers, rather than one generic manufacturer, reported sales in the period of initial generic availability.
48 The volume-weighted ASP for all versions in the HCPCS code was actually $16.20 per mg, because some providers at that point were still dispensing the brand version of the drug.
FINDINGS

continue to fall (possibly because of increasing utilization of generic versions or more generic versions reaching the market), the two-quarter lag has an extended impact because the Medicare payment amount is always slow to reflect the continuously decreasing ASP.

For example, Figure 1 shows the Medicare payment amounts for the antiemetic drug ondansetron hydrochloride over a 2-year period beginning in the first quarter of 2007. During the period of initial generic availability (i.e., first-quarter 2007 through third-quarter 2007), the Medicare payment amount for ondansetron hydrochloride declined by 32 percent. The payment amount continued to decrease each subsequent quarter through the third quarter of 2008, when it was 91 percent less than the payment amount in the first quarter generics were available.

Figure 1: Medicare Payment Amounts and ASPs for Ondansetron Hydrochloride (Oral, 8-mg Version)

Source: CMS’s posted Part B payment limits.
* Represents the first quarter in which generic sales were reflected in the payment amount.

Overall, Medicare payment amounts steadily decreased throughout the first 2 years of generic availability for the drugs under review. On average, after 2 years, the payment amounts were nearly 60 percent less than the original brand-only payment amounts. Because our

49 Two full years of data were available for 13 drugs only; 2 of these 13 drugs were removed from the savings analysis because generic manufacturers did not report any ASPs.
savings analysis included only the first three quarters of each drug’s generic availability, but the decline in payment amounts continued for up to 2 years, the potential savings of $111 million underestimate the total potential savings that would result if the two-quarter lag were eliminated. See Appendix C for a full list of payment amounts for each drug over a 2-year period.

**On average, brand drugs were initially 3 times more expensive than their generic versions**

During the first quarter of generic availability for each drug, the brand versions’ ASPs were, on average, 2.85 times that of their generic equivalents. For 1 drug, the brand ASP was over 10 times that of the generic equivalent in the same quarter.

For three drugs in our analysis, brand versions were priced lower than their generic equivalents in the first quarter of generic availability. However, the payment amounts for all three drugs still showed gradual declines, resulting in potential savings for each. For example, in the first quarter of generic availability, the volume-weighted ASP for brand sumatriptan was over 17 percent lower than that of the generic versions. By two quarters later, however, the generic ASP had dropped 59 percent and the brand ASP had dropped 23 percent, resulting in a decrease in overall volume-weighted ASP of 47 percent. This reflected an overall trend in our analysis, as the entry of first-generic versions resulted in a decline in prices over time, whether because of the emergence of lower-priced generics or the lowering of brand prices.

---

**According to FDA, numerous high-expenditure drugs could have first-generic versions approved in the next several years**

According to FDA, 26 of the 48 brand-only drugs with the highest Part B expenditures have had or may have generic versions approved for the first time in the next several years. Generic versions of these 26 drugs are expected to gain approval in gradually increasing numbers through 2014. These 26 brand drugs had combined Part B expenditures of over $2.8 billion and accounted for 25 percent of Part B

---

50 Data were available for 12 drugs only.

51 Specifically, 4 of the 26 drugs have become generic since our review began; 4 drugs are currently eligible for generic approval; an additional 3 drugs may become generic beginning in 2011; 13 drugs may become generic beginning in 2012; 1 drug may become generic beginning in 2013; and 1 drug may become generic beginning in 2014.
FINDINGS

Drug payments in 2009. If and when these 26 drugs become available in generic form, their payment amounts will be subject to the same two-quarter lag that exists under the ASP-based system.

FDA could not provide exact dates for the expected generic approval of these drugs. Instead, it gave an estimate of the earliest possible date of ANDA approval. The date of actual market entry may differ from this estimate, as external factors, such as patent litigation, may prolong the introduction of generic versions beyond the date of ANDA approval. See Appendix D for a list of these 26 brand-only Part B-covered drugs and their FDA-estimated generic approval times.

Nearly half of the current high-dollar brand-only Part B drugs are biologics; the ACA recently created a pathway for generic approval of biological products

The remaining 22 of the top 48 brand-only Part B-covered drugs are biologics, including the 7 Part B drugs with the highest Medicare expenditures in 2009. Prior to the passage of the ACA, no pathway existed for the approval of generic versions of biologics; however, section 7002 of the ACA provides for approval of biosimilars (i.e., generic biologics). As a result, generic forms of these 22 drugs may gain approval in the future. In 2009, these 22 biologics accounted for over $5.3 billion in Part B spending. See Appendix E for a list of the top 22 biologics under Part B.

Significant obstacles remain in proactively identifying newly available generic drugs

Because of issues such as patent litigation and marketing agreements, the date of FDA’s approval of generic versions often does not coincide with the date of actual generic market entry. In fact, 3 of the 16 generic drugs in our analysis did not reach the market until at least 6 months after FDA’s date of generic approval. See Appendix F for a comparison of the dates of ANDA approvals and the dates of actual generic entry.

Two additional drugs not included in our analysis (gemcitabine and torsemide) were listed by FDA as having had first-generic versions approved during our timeframe (i.e., between first-quarter 2007 and

---

52 Because of barriers to market entry, the complexities of manufacturing these products, and a slightly different payment methodology, biologics may not show the same degree of decline in payment amounts when generic versions reach the market, compared to the drugs identified in this report.
second-quarter 2009), but no generic versions appeared to have reached the market as of the fourth quarter of 2009. In the case of another drug (budesonide), generic versions were approved by FDA and reached the market for a few days, but as a result of patent litigation, generic versions ceased being marketed during the period under review. These issues highlight the complications in predicting when generic versions are likely to become available, making it difficult to anticipate changes in ASPs.

For a number of drugs, generic manufacturers were late to report ASPs or did not report ASPs at all

The first-generic ASPs for two drugs (albuterol sulfate/ipratropium bromide inhalation solution and fomepizole injection) were reported one quarter after the actual generic entry date (see Table 2). Generic manufacturers for two other drugs never reported ASPs to CMS, despite the drugs’ becoming available in generic form.

All four drugs with late or unreported generic ASPs were sold by generic manufacturers that had Medicaid drug rebate agreements with CMS at the time of their market entry and were required to report ASPs in the first quarter in which sales occurred. In instances in which ASPs are reported a quarter late or not at all, the Medicare payment amounts take even longer to reflect sales of generics. Had the manufacturers of these newly available generic drugs reported ASPs in a timely fashion, the potential savings to Part B identified in our analysis could have been even greater.

53 Research into CMS’s background files and manufacturer press releases yielded no evidence of generic versions.
55 The manufacturer-reported ASPs for these drugs were determined to have been submitted late based on the fact that generic manufacturers reported NDCs in the monthly AMP files in the quarter before ASPs were reported in the background files for those same NDCs.
56 No generic ASPs were reported as of the fourth quarter of 2009. We will refer the manufacturers of these two drugs to CMS and work with the agency to undertake appropriate action.
Table 2: First Generics With ASP Reporting Issues

<table>
<thead>
<tr>
<th>HCPCS</th>
<th>Drug Description</th>
<th>FDA Generic Approval Date</th>
<th>Estimated Actual Generic Entry Date</th>
<th>Period Covered by First Reported Generic ASP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q0167</td>
<td>Dronabinol oral, 2.5 mg</td>
<td>June 27, 2008</td>
<td>July 2008</td>
<td>(none listed)</td>
</tr>
<tr>
<td>Q0168</td>
<td>Dronabinol oral, 5 mg</td>
<td>June 27, 2008</td>
<td>July 2008</td>
<td>(none listed)</td>
</tr>
</tbody>
</table>

Source: FDA’s ANDA (Generic) Drug Approvals and OIG analysis.

1 Based on the first appearance of generic manufacturer NDC(s) in the ASP background file. See Appendix A for a description of this analysis.

2 These drugs were not included in our potential savings analysis.

3 No generic ASPs were reported as of fourth-quarter 2009.
This is the second OIG report to identify systemic vulnerabilities in Part B payments for prescription drugs as a result of the two-quarter lag in reimbursement. We found that payment amounts were significantly higher than market prices for an extended period for the newly available generic drugs under review. In other words, during the period of initial generic availability, generic versions of these drugs were being administered or dispensed to beneficiaries, but Medicare was still paying the brand prices.

Although other government and privately sponsored prescription drug programs are designed to take advantage of lower priced generic drugs (e.g., mandatory generic substitution policies), our findings demonstrate that the Part B reimbursement system fails to capture these potential savings for at least two quarters. CMS has expressed interest in exploring options to improve its reimbursement process, but it has yet to make specific changes. With more than half of the top dollar-volume brand drugs covered under Part B potentially gaining approval in generic form over the next 4 years, and the creation under the ACA of a new approval pathway for generic biologics, this vulnerability will likely continue to grow if CMS does not make changes to its Part B payment system.

We therefore recommend that:

**CMS work with Congress to require manufacturers of first generics to submit monthly ASP data during the period of initial generic availability**

If generic manufacturers were required to submit ASP data by the end of each month during the period of initial generic availability, CMS could develop a more appropriate drug payment amount that reflects those generic sales, and set that payment amount for the following quarter. This would substantially reduce the two-quarter lag and would make payment amounts more reflective of actual market prices for newly available generic drugs, thereby taking advantage of their lower prices. CMS could also apply the requirement to manufacturers of generic biologics, once these products begin to be approved.

Our findings also demonstrate that the vulnerability posed by the two-quarter lag is not limited to periods of initial generic availability, as Medicare payment amounts will exceed actual market sales any time ASPs decline. Therefore, if CMS finds that the implementation of a monthly ASP reporting requirement for first generics helps alleviate the financial impact of the two-quarter lag, the agency may wish to consider
transitioning to a monthly ASP reporting system for all Part B-covered drugs.

**AGENCY COMMENTS AND OFFICE OF INSPECTOR GENERAL RESPONSE**

CMS did not concur with our recommendation. CMS stated that requiring manufacturers to submit monthly ASP data would not be feasible for either manufacturers or CMS, and the agency cited the high rates of manufacturer price restatements for monthly AMPs (in contrast to quarterly ASPs) as evidence of the administrative burden of monthly reporting on manufacturers. CMS noted that OIG had identified a number of manufacturers that failed to submit quarterly ASP data, as required, and that this problem could be exacerbated by monthly reporting requirements. The agency recommended that OIG contact these manufacturers to determine why ASPs were not reported and whether any penalties are warranted. CMS went on to state that it is developing a process to identify manufacturers that do not submit quarterly ASPs in a timely manner, and then refer these manufacturers to OIG when appropriate.

CMS also supported the two-quarter lag from a policy perspective, stating that (1) the lag protects Medicare and its beneficiaries from unchecked price increases, as manufacturers may limit raising prices based on their awareness of potential provider reimbursement issues, and (2) the lag leads to the more rapid utilization of generics, as providers have an incentive to quickly switch to lower-priced versions during the limited period when the payment spread is at its highest. CMS also described methods that the agency had considered to lessen the two-quarter lag, and it contended that any policy implementing these approaches would be technically infeasible or lead to more inaccurate and unstable payment rates.

Although the administrative feasibility and compliance burden of any new reporting requirements should be taken into account, OIG believes that the cost savings for Medicare and its beneficiaries that would be achieved by reducing the current reimbursement lag may outweigh any potential issues for CMS and manufacturers. Regarding the latter, OIG is working closely with CMS to improve compliance with price-reporting requirements and recently issued an advisory bulletin notifying manufacturers of a new OIG enforcement initiative that addresses late
RECOMMENDATION

and missing data. As part of this initiative, OIG will consider pursuing penalties for manufacturers that fail to report ASPs.

Furthermore, we do not believe the best protection against price inflation should be a reimbursement system that is slow to reflect market trends, or that the best encouragement for generic substitution is one that causes Medicare and its beneficiaries to pay substantially more than provider costs. Rather, the nature of the volume-weighted ASP-based reimbursement system itself (in which all NDCs assigned to one HCPCS code are paid at the same amount) is an incentive for manufacturers to limit rapid price increases, as well as for providers to utilize generic versions. Yet, because of the two-quarter lag, Part B and its beneficiaries are denied significant potential savings when these generic versions first become available. Although we appreciate CMS’s consideration of alternative price reporting timelines, we note that the methods outlined by CMS in its comments are not the only possible approaches. Therefore, the agency’s conclusions about feasibility and price stability may not apply to other methods that could be used to reduce the reimbursement lag.

CMS also expressed concerns with our savings estimate. The agency stated that:

• it is not clear from the report that the potential savings of $111 million are not annualized savings;
• almost 95 percent of our estimated savings are attributable to three drugs, and therefore not representative of Part B pricing trends overall;
• the savings estimate of $111 million assumes that the lag would be completely eliminated, which is administratively impossible; and
• OIG’s finding regarding the future availability of generic biologics implies significant potential savings; however, it is uncertain that the two-quarter lag would cause payment gaps for these particular products.

As we state in both the methodology and findings sections of the report, our overall savings estimate is not intended to be an annualized figure; rather the $111 million represents the estimated savings had there been no two-quarter lag during the period of initial generic availability (i.e., up to three quarters) for 16 drugs. Because our findings show that the ASPs for these drugs continued to drop beyond the three quarters of analysis, our estimated savings likely would have been significantly
greater had we calculated the total cost of the two-quarter lag for the entire period from January 2007 to June 2009.

In addition, CMS is correct that three drugs account for the vast majority of the $111 million in potential savings. However, we disagree that this means that our results are not representative. In 2009, 64 HCPCS codes accounted for 90 percent of the $11 billion in expenditures for Part B drugs, with only 13 of these codes representing the majority (52 percent) of spending. Therefore, it follows that our estimates would be largely driven by the savings attributable to the few high-dollar drugs that had new generic versions become available during the period under review. Our findings also illustrate that this trend is likely to continue, as 26 brand drugs representing over $2.8 billion and 25 percent of Part B spending may become generic in the next several years.

Furthermore, we realize that it may be impossible to completely eliminate the reimbursement lag, and that our savings estimate presents a best-case scenario. However, given the high cost and substantial expenditures for many Part B drugs, any reduction in the two-quarter lag would lead to significant savings to the program and to Medicare beneficiaries in the form of reduced coinsurance.

Finally, even though the two-quarter lag may or may not affect generic biologics in the same manner as other Part B drugs, the fact that Medicare and its beneficiaries spent $5.3 billion on just 22 biologic products in 2009 means that any delay in taking advantage of even slightly less expensive generic versions would have a profound impact on the program and its beneficiaries.

For the full text of CMS’s comments, see Appendix G.
APPENDIX ~ A

Detailed Methodology for Identifying First-Generic Drugs and Their Dates of Market Entry

1. **The Food and Drug Administration’s (FDA) monthly list of first-generic drug approvals.** We first compiled a list of all drugs listed under FDA’s first-generic drug approvals for all months between January 2007 and June 2009. Because we were interested in identifying drugs which became available within our timeframe, we also included drugs in this analysis that were approved within 2 months before our timeframe (i.e., November 2006) in case any of those drugs actually hit the market starting in January 2007. The FDA list provided the drug name, form, strength, and manufacturer but did not list the Healthcare Common Procedure Coding System (HCPCS) code of each drug. Therefore, we had to search the Centers for Medicare & Medicaid Services’ (CMS) crosswalk files by drug name to identify the drug’s HCPCS code and to determine whether the FDA-listed drug was covered under Part B. If a drug name listed by FDA did not clearly match that in the crosswalk file, we did not include it in the analysis.

2. **CMS’s quarterly background files.** Once we had determined each drug’s HCPCS code, we searched the background files by HCPCS code to identify all manufacturers that reported average sales prices (ASP) for each drug in all quarters in our analysis. Because the first five digits of a national drug code (NDC) denote the manufacturer, we were able to use the NDCs listed in the background files to identify the number of unique manufacturers per drug. We then ran this list of NDCs against the Red Book to exclude any NDCs that the Red Book identified as repackagers. We also excluded any NDCs that CMS had flagged in the background file as being problematic or excluded from the ASP calculation in that quarter. Once we repeated this process in each quarter, we were able to see when a drug went from one manufacturer to multiple manufacturers, thereby indicating the entry of generic versions. The background file also lists a variable to denote whether the drug is a brand or generic version, and this was used as an additional check to confirm that the new manufacturer was marketing a generic version rather than a competing brand version.

3. **CMS’s monthly average manufacturer price (AMP) files.** We used the monthly AMP files to confirm the date of first-generic entry. Because the AMP files list only NDCs and not HCPCS codes, we had to rely
on the NDCs listed in the background files to identify NDCs in the
AMP files.

4. **Red Book.** We repeated the same process used in the AMP analysis
to identify the earliest appearance of an NDC in the Red Book.

5. **Manufacturer press releases.** We researched manufacturer press
releases and Web sites to confirm generic drug NDCs and dates of
market entry.

There were often discrepancies in the dates of generic entry given by the
above data sources. In most instances of discrepancies, we chose the
consensus when most of these data sources were in agreement on the
date of market entry. When the background file was the only data
source to report a different date, we took this to mean that the
manufacturer was late to report ASPs in the background file. In
instances in which there was no clear consensus (3 of the 16 drugs), we
deferred to the earliest listed generic market entry date among all data
sources. For example, if a drug was listed in the background files
starting in first-quarter 2008 but was not listed in the AMP files until
May 2008, we assumed the date of generic market entry was the first
quarter of 2008. If it was not clear whether a drug had first-generic
versions become available within our timeframe, it was not included in
the analysis. We also excluded from our savings analysis drugs from
manufacturers that failed to report any generic NDCs in the
background files.
**Table B-1: First-Generic Drugs Included in Our Analysis**

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Drug Name</th>
<th>Brand Name</th>
<th>First Generic Entry Date</th>
<th>Part B Expenditures During the Three Quarters of Initial Generic Availability</th>
<th>Potential Savings During the Three Quarters of Initial Generic Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0207</td>
<td>Amifostine, inj., 500 milligrams (mg)</td>
<td>Ethyol</td>
<td>May 2008</td>
<td>$8,479,381</td>
<td>$1,364,634</td>
</tr>
<tr>
<td>J0692</td>
<td>Cefepime inj., 500 mg</td>
<td>Maxipime</td>
<td>Jan.–Mar. 2008</td>
<td>$567,286</td>
<td>$48,719</td>
</tr>
<tr>
<td>J1325</td>
<td>Epoprostenol inj., 0.5 mg</td>
<td>Flolan</td>
<td>May 2008</td>
<td>$19,576,492</td>
<td>$66,109</td>
</tr>
<tr>
<td>J1626</td>
<td>Granisetron inj., 0.1 mg</td>
<td>Kytril</td>
<td>Jan. 2008</td>
<td>$13,040,208</td>
<td>$1,816,964</td>
</tr>
<tr>
<td>J3030</td>
<td>Sumatriptan Succinate inj., 6 mg</td>
<td>Imitrex</td>
<td>Feb. 2009</td>
<td>$957</td>
<td>$75</td>
</tr>
<tr>
<td>J7517</td>
<td>Mycophenolate Mofetil oral, 250 mg</td>
<td>Cellcept</td>
<td>May 2009</td>
<td>$132,035,240</td>
<td>$28,958,160</td>
</tr>
<tr>
<td>J7620</td>
<td>Albuterol Sulfate/ Ipratropium Bromide inh. soln., 2.5 mg/0.5 mg</td>
<td>Duoneb</td>
<td>July–Sept. 2007</td>
<td>$165,624,799</td>
<td>$32,073,194</td>
</tr>
<tr>
<td>J9206</td>
<td>Irinotecan inj., 20 mg</td>
<td>Camptosar</td>
<td>Mar. 2008</td>
<td>$90,705,689</td>
<td>$44,131,109</td>
</tr>
<tr>
<td>J9245</td>
<td>Melphalan inj., 50 mg</td>
<td>Alkeran</td>
<td>June 2009</td>
<td>$277,347</td>
<td>$9,909</td>
</tr>
<tr>
<td>J9268</td>
<td>Pentostatin inj., 10 mg</td>
<td>Nipent</td>
<td>Aug. 2007</td>
<td>$3,915,369</td>
<td>$273,111</td>
</tr>
<tr>
<td>Q0166</td>
<td>Granisetron oral, 1 mg</td>
<td>Kytril</td>
<td>Jan. 2008</td>
<td>$649,379</td>
<td>$375,497</td>
</tr>
<tr>
<td>Q0179</td>
<td>Ondansetron oral, 8 mg</td>
<td>Zofran</td>
<td>Jan.–Mar. 2007</td>
<td>$4,296,612</td>
<td>$1,859,387</td>
</tr>
<tr>
<td>Q2009</td>
<td>Fosphenytoin inj., 50 mg</td>
<td>Cerebyx</td>
<td>Aug. 2007</td>
<td>$61</td>
<td>$48</td>
</tr>
<tr>
<td>Q0167²</td>
<td>Dronabinol oral, 2.5 mg</td>
<td>Marinol</td>
<td>July 2008</td>
<td>(n/a)</td>
<td>(n/a)</td>
</tr>
<tr>
<td>Q0168³</td>
<td>Dronabinol oral, 5 mg</td>
<td>Marinol</td>
<td>July 2008</td>
<td>(n/a)</td>
<td>(n/a)</td>
</tr>
</tbody>
</table>

**Total** | **$439,168,842** | **$110,976,913**


¹ For some drugs, we could not determine from the available data the specific month in which generics first became available. For these drugs, we provided the first quarter of generic availability (e.g., January–March 2008).


³ Generic manufacturers for these two drugs did not report any average sales prices and were therefore not included in our savings analysis.
Table C-1: Medicare Payment Amounts for 16 Newly Available Generic Drugs

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Q0 (Brand Only) Payment Amount</td>
<td>$496.281</td>
<td>$8.026</td>
<td>$14.526</td>
<td>$12.924</td>
<td>$5.792</td>
<td>$72.575</td>
<td>$3.190</td>
<td>$1.148</td>
</tr>
<tr>
<td>Q2 Payment Amount</td>
<td>$511.316</td>
<td>$6.749</td>
<td>$14.368</td>
<td>$14.115</td>
<td>$6.046</td>
<td>$84.495</td>
<td>$3.441</td>
<td>$1.079</td>
</tr>
<tr>
<td>Q3 Payment Amount¹</td>
<td>$424.029</td>
<td>$5.711</td>
<td>$14.332</td>
<td>$14.804</td>
<td>$5.341</td>
<td>$82.659</td>
<td>$2.494</td>
<td>$0.805</td>
</tr>
<tr>
<td>Q4 Payment Amount²</td>
<td>$386.293</td>
<td>$5.721</td>
<td>$14.355</td>
<td>$11.850</td>
<td>$4.329</td>
<td>$56.559</td>
<td>$2.600</td>
<td>$0.830</td>
</tr>
<tr>
<td>Q5 Payment Amount</td>
<td>$373.298</td>
<td>$5.249</td>
<td>$14.218</td>
<td>$11.412</td>
<td>$4.053</td>
<td>$43.545</td>
<td>$1.884</td>
<td>$0.581</td>
</tr>
<tr>
<td>Q6 Payment Amount</td>
<td>$367.756</td>
<td>$4.589</td>
<td>$14.101</td>
<td>$10.100</td>
<td>$3.292</td>
<td>$46.678</td>
<td>(data unavailable)</td>
<td>$0.307</td>
</tr>
<tr>
<td>Q7 Payment Amount</td>
<td>$356.806</td>
<td>$4.417</td>
<td>$14.023</td>
<td>$8.753</td>
<td>$2.344</td>
<td>(data unavailable)</td>
<td>(data unavailable)</td>
<td>$0.273</td>
</tr>
<tr>
<td>Q8 Payment Amount</td>
<td>$340.108</td>
<td>$3.781</td>
<td>$14.032</td>
<td>$8.146</td>
<td>$2.004</td>
<td>(data unavailable)</td>
<td>(data unavailable)</td>
<td>$0.243</td>
</tr>
</tbody>
</table>

¹ Quarter and year in parenthesis denote the first quarter in which generics were available.
² Q3 refers to the quarter in which the Medicare payment amount begins to reflect sales of the first generic(s).
³ Q4 refers to the quarter in which the Medicare payment amount fully reflects sales of the first generic(s).

(continued on next page)
Table C-1: Medicare Payment Amounts for 16 Newly Available Generic Drugs (Continued)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Q0 (Brand Only Payment Amount)</td>
<td>$125.800</td>
<td>$1,624.598</td>
<td>$1,934.913</td>
<td>$50.436</td>
<td>$36.064</td>
<td>$5.555</td>
<td>$5.415</td>
<td>$10.835</td>
</tr>
<tr>
<td>Q1 (First Generic Reaches Market Payment Amount)</td>
<td>$126.309</td>
<td>$1,624.598</td>
<td>$1,977.801</td>
<td>$50.224</td>
<td>$36.829</td>
<td>$5.795</td>
<td>$5.387</td>
<td>$11.711</td>
</tr>
<tr>
<td>Q2 Payment Amount</td>
<td>$126.235</td>
<td>$1,624.598</td>
<td>$2,071.219</td>
<td>$46.955</td>
<td>$36.550</td>
<td>$5.813</td>
<td>$5.876</td>
<td>$11.838</td>
</tr>
<tr>
<td>Q3 Payment Amount</td>
<td>$74.753</td>
<td>$1,654.023</td>
<td>$1,858.684</td>
<td>$17.173</td>
<td>$25.029</td>
<td>$3.595</td>
<td>$5.822</td>
<td>$11.508</td>
</tr>
<tr>
<td>Q4 Payment Amount</td>
<td>$36.997</td>
<td>$1,549.472</td>
<td>$1,828.915</td>
<td>$17.877</td>
<td>$18.543</td>
<td>$0.817</td>
<td>$5.824</td>
<td>$11.676</td>
</tr>
<tr>
<td>Q6 Payment Amount</td>
<td>$18.296</td>
<td>(data unavailable)</td>
<td>$1,622.651</td>
<td>$9.244</td>
<td>$4.604</td>
<td>$0.728</td>
<td>$6.795</td>
<td>$13.567</td>
</tr>
<tr>
<td>Q7 Payment Amount</td>
<td>$14.955</td>
<td>(data unavailable)</td>
<td>$1,601.255</td>
<td>$5.261</td>
<td>$3.160</td>
<td>$0.607</td>
<td>$6.809</td>
<td>$13.604</td>
</tr>
<tr>
<td>Q8 Payment Amount</td>
<td>$13.433</td>
<td>(data unavailable)</td>
<td>$1,447.688</td>
<td>$7.082</td>
<td>$3.938</td>
<td>$0.617</td>
<td>$7.169</td>
<td>$14.165</td>
</tr>
</tbody>
</table>

Source: Centers for Medicare & Medicaid Services' posted Part B payment limits.

1 Quarter and year in parenthesis denote the first quarter in which generics were available.

2 Not included in our savings analysis.

3 Q3 refers to the quarter in which the Medicare payment amount begins to reflect sales of the first generic(s).

4 Q4 refers to the quarter in which the Medicare payment amount fully reflects sales of the first generic(s).
Table D-1: Estimated Generic Approval Timeline for the Top 26 Dollar-Volume Brand-Only Part B Drugs (Biologics Excluded), According to FDA

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>FDA-Estimated Generic Approval Timeline¹</th>
<th>2009 Part B Expenditures²</th>
<th>2009 Part B Rank³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxaliplatin</td>
<td>Eloxatin</td>
<td>Approved in generic form⁴</td>
<td>$307,305,870</td>
<td>8</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>Taxotere</td>
<td>After February 10, 2012</td>
<td>$273,059,887</td>
<td>9</td>
</tr>
<tr>
<td>Zoledronic acid</td>
<td>Zometa</td>
<td>After April 30, 2012</td>
<td>$228,200,463</td>
<td>12</td>
</tr>
<tr>
<td>Pemetrexed</td>
<td>Alimta</td>
<td>Currently eligible for approval</td>
<td>$224,725,011</td>
<td>13</td>
</tr>
<tr>
<td>Gemcitabine hydrochloride</td>
<td>Gemzar</td>
<td>Approved in generic form</td>
<td>$214,841,468</td>
<td>14</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>Velcade</td>
<td>After August 31, 2011</td>
<td>$157,915,565</td>
<td>19</td>
</tr>
<tr>
<td>Leuprolide acetate</td>
<td>Lupron</td>
<td>Approved in generic form</td>
<td>$148,807,207</td>
<td>20</td>
</tr>
<tr>
<td>Palonosetron hydrochloride</td>
<td>Aloxi</td>
<td>After April 30, 2012</td>
<td>$141,432,119</td>
<td>22</td>
</tr>
<tr>
<td>Treprostil sodium</td>
<td>Remodulin</td>
<td>After April 30, 2012</td>
<td>$112,277,602</td>
<td>26</td>
</tr>
<tr>
<td>Octreotide acetate</td>
<td>Sandostatin Lar Depot</td>
<td>After April 30, 2012</td>
<td>$107,672,719</td>
<td>28</td>
</tr>
<tr>
<td>Azacitidine</td>
<td>Vidaza</td>
<td>After May 19, 2011</td>
<td>$101,648,346</td>
<td>29</td>
</tr>
<tr>
<td>Zoledronic acid</td>
<td>Reclast</td>
<td>After May 18, 2011</td>
<td>$100,768,293</td>
<td>30</td>
</tr>
<tr>
<td>Arformoterol tartrate</td>
<td>Brovana</td>
<td>After March 30, 2012</td>
<td>$77,081,333</td>
<td>32</td>
</tr>
<tr>
<td>Paclitaxel protein-bound</td>
<td>Abraxane</td>
<td>After April 30, 2012</td>
<td>$72,033,094</td>
<td>36</td>
</tr>
<tr>
<td>Adenosine</td>
<td>Adenoscan</td>
<td>Currently eligible for approval</td>
<td>$69,316,718</td>
<td>39</td>
</tr>
<tr>
<td>Triptorelin pamoate</td>
<td>Trestar</td>
<td>After April 30, 2012</td>
<td>$67,684,223</td>
<td>40</td>
</tr>
<tr>
<td>Decitabine</td>
<td>Dacogen</td>
<td>After May 2, 2013</td>
<td>$62,196,704</td>
<td>42</td>
</tr>
<tr>
<td>Doxorubicin hydrochloride liposome</td>
<td>Doxil</td>
<td>After May 17, 2014</td>
<td>$49,619,144</td>
<td>47</td>
</tr>
<tr>
<td>Iloprost</td>
<td>Ventavis</td>
<td>Currently eligible for approval</td>
<td>$48,970,602</td>
<td>48</td>
</tr>
<tr>
<td>Mycophenolate acid</td>
<td>Myfortic</td>
<td>After January 17, 2012</td>
<td>$46,469,720</td>
<td>51</td>
</tr>
<tr>
<td>Sirolimus</td>
<td>Rapamune</td>
<td>After April 30, 2012</td>
<td>$45,449,381</td>
<td>52</td>
</tr>
<tr>
<td>Topotecan hydrochloride</td>
<td>Hycamtin</td>
<td>Approved in generic form</td>
<td>$43,430,255</td>
<td>54</td>
</tr>
<tr>
<td>Fulvestrant</td>
<td>Faslodex</td>
<td>After March 30, 2012</td>
<td>$40,709,396</td>
<td>57</td>
</tr>
<tr>
<td>Ibandronate sodium</td>
<td>Boniva</td>
<td>Currently eligible for approval</td>
<td>$25,710,811</td>
<td>66</td>
</tr>
<tr>
<td>Imiglucerase</td>
<td>Cerezyme</td>
<td>After April 30, 2012</td>
<td>$24,355,150</td>
<td>70</td>
</tr>
<tr>
<td>Verteporfin</td>
<td>Visudyne</td>
<td>After April 30, 2012</td>
<td>$17,308,914</td>
<td>80</td>
</tr>
</tbody>
</table>

Total $2,808,899,996

Source: Food and Drug Administration (FDA) analysis of Part B drugs, 2009.

¹ Approximate date of April 30, 2012, is used by FDA to estimate how long it would take to approve an abbreviated new drug application if it is submitted before November 10, 2009, with a Paragraph IV Patent Certification.
³ Rankings include single-source drugs, multiple-source drugs, and biologics.
⁴ Generic versions of this drug were initially approved and marketed, but litigation brought by the brand manufacturer against the generic manufacturers resulted in the discontinuation of generic sales.
### Table E-1: Top 22 Dollar-Volume Biologics Under Part B

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>2009 Part B Expenditures</th>
<th>2009 Part B Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranibizumab</td>
<td>Lucentis</td>
<td>$814,869,580</td>
<td>1</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Rituxan</td>
<td>$807,136,671</td>
<td>2</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Avastin</td>
<td>$723,336,581</td>
<td>3</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Remicade</td>
<td>$605,603,464</td>
<td>4</td>
</tr>
<tr>
<td>Pegfilgrastim</td>
<td>Neulasta</td>
<td>$493,786,366</td>
<td>5</td>
</tr>
<tr>
<td>Darbepoetin alfa</td>
<td>Aranesp</td>
<td>$426,599,502</td>
<td>6</td>
</tr>
<tr>
<td>Epoetin alfa</td>
<td>Epogen/Procrit</td>
<td>$332,792,303</td>
<td>7</td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>Herceptin</td>
<td>$211,603,637</td>
<td>15</td>
</tr>
<tr>
<td>Celuximab</td>
<td>Erbitux</td>
<td>$165,132,074</td>
<td>18</td>
</tr>
<tr>
<td>Abatacept</td>
<td>Orencia</td>
<td>$145,050,591</td>
<td>21</td>
</tr>
<tr>
<td>Anthemophilic factor VIII (Recombinant)</td>
<td>(All brands)</td>
<td>$125,289,250</td>
<td>24</td>
</tr>
<tr>
<td>Botulinum toxin type A</td>
<td>Botox</td>
<td>$88,997,730</td>
<td>31</td>
</tr>
<tr>
<td>Coagulation factor VIIa</td>
<td>Novoseven</td>
<td>$74,330,848</td>
<td>33</td>
</tr>
<tr>
<td>Filgrastim</td>
<td>Neupogen</td>
<td>$69,897,511</td>
<td>38</td>
</tr>
<tr>
<td>Natalizumab</td>
<td>Tysabri</td>
<td>$54,497,650</td>
<td>46</td>
</tr>
<tr>
<td>Omalizumab</td>
<td>Xolair</td>
<td>$43,285,268</td>
<td>55</td>
</tr>
<tr>
<td>Immune globulin</td>
<td>Vivaglobin</td>
<td>$42,709,895</td>
<td>56</td>
</tr>
<tr>
<td>Immune globulin</td>
<td>Gammagard Liquid</td>
<td>$30,226,662</td>
<td>61</td>
</tr>
<tr>
<td>Panitumumab</td>
<td>Vectibix</td>
<td>$27,170,683</td>
<td>63</td>
</tr>
<tr>
<td>Coagulation factor IX Recombinant</td>
<td>Benefix</td>
<td>$25,176,467</td>
<td>67</td>
</tr>
<tr>
<td>Anthemophilic factor VIII:C Human</td>
<td>(All brands)</td>
<td>$24,453,801</td>
<td>69</td>
</tr>
<tr>
<td>Immune globulin, powder</td>
<td>(All brands)</td>
<td>$21,200,286</td>
<td>74</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>$5,353,148,820</strong></td>
<td></td>
</tr>
</tbody>
</table>


2 Rankings include single-source drugs, multiple-source drugs, and biologics.
Table F-1: Comparison of FDA’s ANDA Approval Dates and Actual Generic Entry Dates

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Drug Name</th>
<th>FDA Generic Approval Date</th>
<th>Estimated Actual Generic Entry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9245</td>
<td>Melphalan inj.</td>
<td>June 9, 2009</td>
<td>June 2009</td>
</tr>
<tr>
<td>Q0167</td>
<td>Dronabinol oral, 2.5 mg</td>
<td>June 27, 2008</td>
<td>July 2008</td>
</tr>
<tr>
<td>Q0168</td>
<td>Dronabinol oral, 5 mg</td>
<td>June 27, 2008</td>
<td>July 2008</td>
</tr>
</tbody>
</table>

First Generics With Conflicting Entry Dates

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Drug Name</th>
<th>FDA Generic Approval Date</th>
<th>Estimated Actual Generic Entry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J7517</td>
<td>Mycophenolate mofetil oral</td>
<td>July 29, 2008</td>
<td>May 2009</td>
</tr>
<tr>
<td></td>
<td>ipratropium bromide inh. soln.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FDA-Identified First Generics Which Did Not Come to Market

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Drug Name</th>
<th>FDA Generic Approval Date</th>
<th>(Generics did not come to market)</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9201</td>
<td>Gemcitabine inj.</td>
<td>Dec. 18, 2008</td>
<td>(Generics did not come to market)</td>
</tr>
<tr>
<td>J3285</td>
<td>Torsemide inj.</td>
<td>June 10, 2008</td>
<td>(Generics did not come to market)</td>
</tr>
</tbody>
</table>

FDA-Identified First Generics Which Temporarily Came to Market

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Drug Name</th>
<th>FDA Generic Approval Date</th>
<th>(Products were launched in Nov. 2008 and ceased being distributed for sale by the generic manufacturer later that month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>J7626</td>
<td>Budesonide inh. soln.</td>
<td>Nov. 18, 2008</td>
<td>(Products were launched in Nov. 2008 and ceased being distributed for sale by the generic manufacturer later that month)</td>
</tr>
</tbody>
</table>


1 These drugs were not included in our savings analysis.

2 No generics available as of fourth-quarter 2009.
Agency Comments

DATE: OCT 07 2010

TO: Daniel R. Levinson
Inspector General

FROM: Donald Berwick, M.D., Administrator


The Centers for Medicare & Medicaid Services (CMS) appreciates the opportunity to review and respond to the OIG Draft Report entitled, “Medicare Payments for Newly Available Generic Drugs” (OEI-03-09-00510). We appreciate the OIG’s continuing efforts to examine payment made under the average sales price (ASP) methodology.

The OIG report presents findings from a comparison of Medicare payment amounts to market prices for certain newly available generic drugs. The report finds differences between the Medicare payment limits and the market prices for the generic drugs and attributes these differences primarily to the “two-quarter lag” inherent in the Medicare payment limit calculation process. The OIG claims that Medicare could have saved $111 million if Medicare payment limits had reflected sales prices during the period of initial generic availability of 16 different drugs, and, therefore, urges that the two quarter lag be eliminated.

However, this estimate is based on the premise that no time lag would exist between the introduction and inclusion of generics in the ASP. Such potential savings could not be achieved because any calculation of payment that relies on manufacturer reporting would require a lag time to allow manufacturers to calculate and submit their pricing data. Moreover, the OIG’s estimate also assumes that providers would immediately switch from branded to generic products without factoring the lag time associated with the introduction of any new product in the market. In addition, it is not clear from the report that the $111 million is not an annualized savings amount, but instead a sum of potential savings over the course of several years.

CMS notes that almost 95 percent of the OIG’s reported savings are attributed to three drugs and, therefore, the OIG’s savings projections may not be accurate. Nearly $105 million of the $111 million in projected savings is attributed to three products, mycophenolate mofetil (generic CellCept), albuterol sulfate/ipratropium Bromide (generic DuoNeb) and irinotecan (generic Camptosar). We do not believe that extrapolating savings projections that are based on such a small subset of drugs to all generic drugs correctly represents Part B drug price changes due to the introduction of generic drugs.
The OIG also found that “nearly half of the high-dollar brand-only Part B drugs are biologics” and implies that significant future savings could be realized by more closely aligning Medicare payment amounts with sales prices for biosimilar biologics. Given that the Affordable Care Act (ACA) establishes a new pricing methodology for Medicare payments for biosimilars that is different from the traditional ASP methodology for brand drugs and their generics, we are uncertain that pricing gaps between Medicare payments and market prices for biosimilar biologics would occur.

Finally, the OIG report notes that a number of generic manufacturers failed to report ASP information to CMS. CMS shares the OIG’s interest in seeing timely and accurate reporting of ASP information. To that end, we have begun to develop processes for proactively identifying and contacting late and non-reporting manufacturers and for making appropriate and timely referrals to the OIG. For those manufacturers identified by the OIG in this report, we recommend that the OIG contact the manufacturer directly to determine why ASP was not reported and whether any penalties may be appropriate. We note that the issue of generic manufacturers not reporting ASP could be exacerbated if manufacturers were required to report monthly rather than quarterly. In other words, we believe that requiring more frequent reporting could result in more frequent and longer delays in our receipt of information, which would, in turn, result in delays in calculating Medicare payment amounts. Such a result could, in our view, decrease the stability of such payment amounts.

**OIG RECOMMENDATION**

The OIG recommends that CMS “work with Congress to require manufacturers of first generics to submit monthly ASP data during the period of initial generic availability.” Specifically, the OIG suggests that CMS collect ASP data by the end of each month and then develop a payment amount for the following quarter using the data.

**CMS RESPONSE**

We do not concur with this recommendation. Except for Part B drugs, Medicare payment systems are updated on an annual basis. Some are updated on a fiscal year basis while others are updated on a calendar year basis, but the comprehensive pricing files for many different Medicare payment systems are updated on an annual basis. The ASP payment methodology, in contrast, requires quarterly updates by statute. In requiring quarterly price updates, Congress struck a balance between updating more frequently than the annual update for all other payment systems with a practical and administratively feasible approach for quarterly updating of payment rates for Part B drugs.

The statute requires that manufacturers submit ASP data to the Secretary not later than 30 days after the close of the quarter. Congress undoubtedly knew that it would take some time after manufacturers submit the data for CMS to verify and perform quality assurance checks prior to assigning the 11-digit national drug code (NDC) codes to 5-digit HCPCS codes, calculating payment rates pursuant to the statutory formulas, and posting the new rates as well as for Medicare contractors to test and install a new pricing file to be used for payment. We note that
the two-quarter lag works in both directions — reductions in prices for drugs during a quarter, such as from the availability of generic drugs, take two quarters to be reflected in Medicare payment rates, but increases in sales prices for drugs also take two quarters to be reflected in Medicare payment rates.

A gradual increase over time in Medicare payment limits for most high volume drugs supports our position that the “two-quarter lag” provides beneficiaries and the Medicare program a degree of protection from unchecked upward movement of prices by manufacturers due to business-related decisions. Manufacturers know that price increases are not immediately reflected in Medicare payment limits and thus may strive to limit the degree to which prices increase. The “two-quarter lag” also serves as an incentive for generic uptake. A time-limited incentive for physicians to quickly adopt the use of generic drugs such as the “two-quarter lag” also provides a level of encouragement for generic manufacturers to market new generic drugs as quickly as possible.

In responding to a previous OIG report that recommended that CMS explore options to expedite the reimbursement process to ensure that payment amounts reflect sales prices more quickly, CMS explored several alternative approaches to gathering data and calculating Medicare payment limits. The options CMS explored involve elements of the OIG’s current recommendation. However, it is important to note that the ASP methodology, including data submission requirements, are established in statute and changes would require legislative changes. Even if such legislative changes were made, we do not believe that any of these options would be administratively feasible for manufacturers or CMS.

CMS considered trying to shorten the lag by requiring manufacturers to submit data by the last day of the quarter in which the sales occurred, rather than 30 days after the end of the quarter. CMS does not believe that manufacturers would have complete and accurate data on sales for a quarter by the last day of the quarter, but use the additional time to calculate accurate sales information, including information on discounts and rebates paid, for the quarter. CMS does not believe that this approach would be technically feasible for manufacturers or that it would result in more accurate data on sales.

A policy that would require manufacturers to report sales prices monthly, 30 days after the close of the month and used to calculate quarterly Medicare payment limits, also poses challenges. In this case, quarterly data would have to be computed for each NDC from a manufacturer. CMS would need to volume weight the data monthly and combine three months of data to arrive at a quarterly Medicare payment limit for each code. Such an approach could lead to more inaccurate and unstable payment rates. The more frequently that manufacturers submit data, the more opportunity that there will be for errors. The relatively low number of ASP restatements by manufacturers versus the relatively high number of average manufacturer price restatements by the same manufacturers is evidence of the administrative burden of monthly reporting on manufacturers. Requiring manufacturers to report by the end of each month also may increase failure rates for reporting.

Further, a policy of determining ASP payment rates on a monthly basis could lead to more instability in payments, and would be administratively and operationally infeasible. We believe
that such an approach would provide incentives for manufacturers to raise prices, in turn making beneficiaries responsible for higher coinsurance payments.

CMS also considered an approach that would require monthly manufacturer submission of data by the end of the month. CMS believes that this approach is the OIG’s recommendation. We believe that this approach encompasses the weaknesses outlined above that are associated with both the submission of data by the end of a quarter or month, as well as submission of monthly data. We also believe that it would be difficult to limit the OIG’s recommendation to new generic drugs. Application of the recommendation to all Part B drugs not only would be administratively impractical, but also would expose beneficiaries and the Medicare program to higher payments when drug prices increase.

While CMS appreciates the concern regarding how to incorporate lower generic prices more quickly into Medicare’s payment system, CMS disagrees with this OIG recommendation. We appreciate the OIG’s interest in Medicare drug payment issues. CMS will continue to work with the OIG to improve the quality and value of care delivered to all Medicare beneficiaries.
Technical Comments

- In discussing the saving potential, the report refers to the "20 percent beneficiary copayment". Part B drugs furnished by physicians and other suppliers involve beneficiary coinsurance rather than copayment.

- Technically, it appears that the $111 million figure is not the Medicare savings, but the sum of the Medicare and beneficiary savings since the figure seems to be calculated based on allowed charges before application of coinsurance.

- The OIG’s recommendation is to have generic products reflected in ASP prices in the quarter immediately after a generic goes on sale. This timeframe is much shorter than that used to calculate the estimated $111 million in Medicare savings. Consequently, any actual savings associated with implementation of the OIG’s recommendation would probably be more modest than the OIG estimates because there would not be as marked a price discrepancy in the quarters after the generic products are included in the ASP volume weighted calculation.
This report was prepared under the direction of Robert A. Vito, Regional Inspector General for Evaluation and Inspections in the Philadelphia regional office, and David E. Tawes, Director of the Medicare and Medicaid Prescription Drug Unit.

Kevin McAloon served as lead analyst for this study. Central office staff who contributed include Natasha Franklin, Kevin Manley, and Scott Manley.
Office of Inspector General
http://oig.hhs.gov

The mission of the Office of Inspector General (OIG), as mandated by Public Law 95-452, as amended, is to protect the integrity of the Department of Health and Human Services (HHS) programs, as well as the health and welfare of beneficiaries served by those programs. This statutory mission is carried out through a nationwide network of audits, investigations, and inspections conducted by the following operating components:

Office of Audit Services
The Office of Audit Services (OAS) provides auditing services for HHS, either by conducting audits with its own audit resources or by overseeing audit work done by others. Audits examine the performance of HHS programs and/or its grantees and contractors in carrying out their respective responsibilities and are intended to provide independent assessments of HHS programs and operations. These assessments help reduce waste, abuse, and mismanagement and promote economy and efficiency throughout HHS.

Office of Evaluation and Inspections
The Office of Evaluation and Inspections (OEI) conducts national evaluations to provide HHS, Congress, and the public with timely, useful, and reliable information on significant issues. These evaluations focus on preventing fraud, waste, or abuse and promoting economy, efficiency, and effectiveness of departmental programs. To promote impact, OEI reports also present practical recommendations for improving program operations.

Office of Investigations
The Office of Investigations (OI) conducts criminal, civil, and administrative investigations of fraud and misconduct related to HHS programs, operations, and beneficiaries. With investigators working in all 50 States and the District of Columbia, OI utilizes its resources by actively coordinating with the Department of Justice and other Federal, State, and local law enforcement authorities. The investigative efforts of OI often lead to criminal convictions, administrative sanctions, and/or civil monetary penalties.

Office of Counsel to the Inspector General
The Office of Counsel to the Inspector General (OCIG) provides general legal services to OIG, rendering advice and opinions on HHS programs and operations and providing all legal support for OIG’s internal operations. OCIG represents OIG in all civil and administrative fraud and abuse cases involving HHS programs, including False Claims Act, program exclusion, and civil monetary penalty cases. In connection with these cases, OCIG also negotiates and monitors corporate integrity agreements. OCIG renders advisory opinions, issues compliance program guidance, publishes fraud alerts, and provides other guidance to the health care industry concerning the anti-kickback statute and other OIG enforcement authorities.